arrow
Return

Alvimopan

delete2008-01-01
delete11
PRE
AI
C
Curran, Monique P. *
R
Robyns, Gayle W.
S
Scott, Lesley J.
P
Perry, Caroline M.
DOI:10.2165/00003495-200868140-00006delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Alvimopan, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, is a selective, peripherally acting p-opioid receptor antagonist that is available for short-term use in hospitalized patients who have undergone bowel resection. The efficacy of alvimopan in the management of postoperative ileus has been evaluated in five phase III trials; four conducted in North America and one conducted in Europe/Australasia. Patients who had undergone partial large or small bowel resection surgery with primary anastomosis were randomized to receive alvimopan 12 mg or placebo as a single oral pre-operative dose followed by twice-daily administration for up to 7 days postoperatively. In the five phase III trials, alvimopan was significantly more effective than placebo in reducing the time to recovery of upper and lower gastrointestinal (GI) function, as assessed using a two-component endpoint (GI2) comprising time to tolerance of solid food and first bowel movement. The mean time to reach the GI2 endpoint was 11-26 hours sooner with alvimopan than with placebo. In the phase III trials conducted in North America, the time to writing the hospital discharge order was 13-21 hours sooner with alvimopan than with placebo. Alvimopan did not reduce opicid-induced analgesia and/or increase the amount of opioids administered postoperatively. Short-term alvimopan was generally well tolerated in adults undergoing bowel resection.
Keywords:
MAJOR ABDOMINAL-SURGERY
MU-OPIOID RECEPTOR
PHASE-III TRIAL
POSTOPERATIVE ILEUS
DOUBLE-BLIND
ANTAGONIST
PLACEBO

Journal

Drugs cover
Drugs
IF:
14.4
Papers:
8.4K
Citations:
2.3W

Organization

A
adis international
Scholars:
102
Papers: 386
Citations: 0
Cited Papers

Cited Papers

Caricaturing facial expressions
err2000-08-01
err0
PREAI
errAndrew J. Calder; Duncan Rowland; Andrew W. Young; Ian Nimmo-Smith; Jill Keane; David I. Perrett
errShare
errSave
Herbal supplement usage among cancer patients
err2021-01-01
err0
errOAAI
errThirunavukkarasu Kanimozhi; Kalluru Hindu; Yuvaraj Maheshvari; Y. Gulab Khushnidha; Mahendrian Kumaravel; K. Satish Srinivas; M. Manickavasagam; Kalachaveedu Mangathayaru
errShare
errSave
Effect of alvimopan and codeine on gastrointestinal transit: A randomized controlled study
err2005-08-01
err95
errOAAI
errGonenne, J; Camilleri, M; Ferber, I; Burton, D; Baxter, K; Keyashian, K; Foss, J; Wallin, B; Du, W; Zinsmeister, AR
errShare
errSave
Phase III Trial of Alvimopan, a novel, peripherally acting, Mu Opioid antagonist, for postoperative ileus after major abdominal surgery
err2005-06-01
err180
PREAI
errDelaney, CP; Weese, JL; Hyman, NH; Bauer, J; Techner, L; Gabriel, K; Du, W; Schmidt, WK; Wallin, BA
errShare
errSave
researcher View more